Physician profile

Edward John Lind, II

Family Medicine · Wichita, KS

NPI 1316956055

$2,397.02

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $557.35 2019-2020
Astrazeneca Pharmaceuticals LP $370.78 2019-2020
Amgen INC. $311.92 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $196.12 2019-2020
Welch Allyn $177.38 2021
Amarin Pharma, INC. $132.90 2019-2020
Sanofi-Aventis U.S. LLC $120.48 2019-2020
Astellas Pharma US INC $120.06 2019-2020
Glaxosmithkline, LLC. $112.81 2019
Antares Pharma, INC. $42.93 2019-2020
Merck Sharp & Dohme LLC $42.85 2019
Novartis Pharmaceuticals Corporation $36.28 2019
Mylan Specialty L.P. $34.67 2019
Takeda Pharmaceuticals U.S.A., INC. $24.13 2019
Janssen Pharmaceuticals, INC $23.55 2019
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Vivus LLC $20.99 2019
Radius Health, INC. $17.81 2019
Pfizer INC. $15.93 2019
Ferring Pharmaceuticals INC. $13.92 2020
Nalpropion Pharmaceuticals LLC $13.37 2019
Lilly USA, LLC $10.79 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Edward John Lind, II

$2,397.02

in general payments reported 2019-2025

Years
2019-2021
Top company
Novo Nordisk INC

https://glasscript.com/doctor/59977/edward-john-lind

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.